| Description |
Poorly soluble compounds represent roughly 60% of compounds in drug development, and this figure is only likely to increase. Pharma IQ’s 3rd annual Improving Solubility conference is an essential event for any scientist dealing with poorly soluble compounds, bringing together discovery chemistry and support, preformulation and formulation. Through practical case studies it will explore methods to predict and measure solubility, and strategies for solubility enhancement, including solid state and a range of formulation approaches. Through leading industry examples and in-depth discussion it will uncover best practices to help delegates increase the chances of development success for their poorly soluble compounds.
|
|
| Additional Information |
Leab Sek, Senior Development Scientist, Formulation & Process Design, Merck Sharp & Dohme
Shawn Yin, Senior Research Investigator, Bristol-Myers Squibb
James Cunningham, Research Fellow, Pharmaceutical R&D, Merck & Co.
Gary Eichenbaum, Principal Scientist / Project Leader, Global Preclinical Development, Johnson & Johnson PRD
Li Di, Principal Scientist, Wyeth Research
Paul Sutton, Fellow, Novartis Pharmaceuticals
Rolf Brickl, Scientific Expert, Pharmaceutical R&D, Boehringer Ingelheim
|
|
